scholarly journals EGF-induced urokinase plasminogen activator receptor promotes epithelial to mesenchymal transition in human gastric cancer cells

2017 ◽  
Vol 38 (4) ◽  
pp. 2325-2334 ◽  
Author(s):  
Pingping Wang ◽  
Maoyuan Ma ◽  
Shanhui Zhang
Keyword(s):  
Gastric Cancer ◽  
Cancer Cells ◽  
Plasminogen Activator ◽  
Epithelial To Mesenchymal Transition ◽  
Urokinase Plasminogen Activator ◽  
Human Gastric Cancer ◽  
Gastric Cancer Cells ◽  
Urokinase Plasminogen Activator Receptor ◽  
Mesenchymal Transition ◽  
Plasminogen Activator Receptor

scholarly journals Bufalin inhibits the growth and epithelial to mesenchymal transition of human gastric cancer cells via modulation of MEK/ERK pathway

2021 ◽  
Vol 16 (1) ◽  
pp. 27-33
Author(s):  
Yi Zhou ◽  
Liguo Wang ◽  
Hui Lin ◽  
Yunxia Wang ◽  
Kezhu Hou
Keyword(s):  
Gastric Cancer ◽  
Cell Cycle ◽  
Cell Cycle Arrest ◽  
Cancer Cells ◽  
Epithelial To Mesenchymal Transition ◽  
Human Gastric Cancer ◽  
M Cell ◽  
Gastric Cancer Cells ◽  
Mesenchymal Transition ◽  
Cycle Arrest

This study was designed to evaluate the anti-cancer effects of bufalin against the human gastric cancer cells and unveil the underlying mechanism. The results showed that bufalin inhibited the proliferation and colony formation of the MGC-803 gastric cancer cells and exhibited an IC50 of 10 μM. These antiproliferative effects were found to be due to the induction of G2/M cell cycle arrest. The G2/M cell cycle arrest was also concomitant with inhibition of cdc2, cdc25 and cyclin B1. Furthermore, bufalin suppressed the epithelial-to-mesenchymal transition, migration, and invasion of the MGC-803 gastric cancer cells. The Western blot analysis revealed that bufalin exerted its effects via deactivation of EK/ERK signaling pathway. Taken together, these results suggest the potential of bufalin as the lead molecule for the development of chemotherapy for gastric cancer.  

Sign in / Sign up

Export Citation Format

Share Document